This trial studies how well advanced magnetic resonance imaging (MRI) methods, called magnetic resonance fingerprinting (MR fingerprinting) and Q-space trajectory imaging (QTI), work in producing detailed images of the body's organs and structures in patients with gynecologic tumors that are new (primary) or have come back (recurrent) or benign (non-cancerous) uterine fibroids. Using these new methods may provide doctors with more information in characterizing gynecological tumors compared to standard of care MRI.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03993210.
PRIMARY OBJECTIVE:
I. To investigate the feasibility of advanced MRI sequences in participants with gynecologic malignancy and in control participants with benign uterine fibroids by measures of image quality and by comparing the MRI parameters between different tumor entities and normal anatomic structures.
SECONDARY OBJECTIVES:
I. To study the diagnostic value of MRF and QTI in characterizing the tumor by comparing the tumor parameters with normal structures, benign fibroids, and tumor histology.
II. To study the prognostic value of MRF and QTI by comparing tumor parameters with treatment effect and participant outcome.
OUTLINE:
Patients undergo standard of care pelvic MRI over 30-45 minutes then undergo MRF or QTI over 10-15 minutes.
After completion of study, patients are followed for up to 4 years.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorClare M.C. Tempany-Afdhal
